Clinical and molecular characterizations of novel POU3F4 mutations reveal that DFN3 is due to null function of POU3F4 protein

Hee Keun Lee,1,* Mee Hyun Song,2,7* Myungmo Kang,3 Jung Tae Lee,4 Kyoung-Ah Kong,3 Su-Jin Choi,1 Kyu Yup Lee,5 Hanka Venselaar,6 Gert Vriend,6 Won-Sang Lee,7 Hong-Joon Park,8 Taeg Kyu Kwon,4 Jinwoong Bok,3 and Un-Kyung Kim1

1Department of Biology, Kyungpook National University, Daegu; 2Department of Otorhinolaryngology, Kwandong University College of Medicine, Goyang; 3Department of Anatomy, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul; 4Department of Immunology, Keimyung University School of Medicine; 5Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Kyungpook National University, Daegu, South Korea; 6Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 7Department of Otorhinolaryngology, Yonsei University College of Medicine; and 8Soree Ear Clinic, Seoul, South Korea

Submitted 15 June 2009; accepted in final form 4 August 2009

CONGENITAL HEARING LOSS is one of the most common sensory disorders in humans, affecting approximately one in 1,000 newborns (24). More than 50% of the congenital hearing loss is due to genetic causes, and the majority of these hereditary cases are nonsyndromic. While most genetic nonsyndromic hearing loss is caused by mutations in autosomal genes, X-linked cases are less frequent. Both DFN3 and DFN4 account for almost 50% of all families carrying X-linked nonsyndromic hearing loss (26). Clinical characteristics of DFN3 in affected males include temporal bone abnormalities, stapes fixation, and, in most cases, a mixed type of hearing loss, which is often progressive (7, 8, 10). Anatomical anomalies of the temporal bone revealed by computer-assisted tomography (CT) include dilatation of the lateral end of the internal acoustic canal (IAC), abnormally wide communication between the IAC and inner ear compartment, and, sometimes, partial hypoplasia of the cochlea (8, 27). As a result of the widening of the bony IAC, cerebrospinal fluid can enter the vestibule, which is thought to underlie the reported “gusher” phenomenon, described as fluid gushing out upon removal of the stapes footplate during corrective surgery (8). Female carriers of a mutation in the DFN3 locus typically show little or no hearing loss (26).

Deafness segregating at the DFN3 locus is associated with mutations in the POU3F4 gene (11). POU3F4 belongs to a superfamily of POU domain transcription factors, which are characterized by a conserved bipartite DNA binding domain. This domain consists of a POU-specific domain and a POU homeodomain. POU3F4 is expressed in the inner ear during embryogenesis but is restricted to the forebrain in adults (20, 22). Pou3f4 knockout mice also display malformations in tissues that do not normally express Pou3f4 such as the mesenchymal tissue adjacent to the otic epithelium (28, 29). Targeted deletion of Pou3f4 in mice results in abnormalities mainly in the mesenchyme-derived structures such as the spiral limbus, the scala tympani, and strial fibrocytes of the cochlea, as well as defects in the temporal bone (23, 29). In addition, Pou3f4 knockout mice also display malformations in tissues that do not normally express Pou3f4 such as the stapes of the middle ear and the membranous components of the cochlea, indicating possible roles of Pou3f4
in reciprocal interactions between peri-otic mesenchyme and other tissues such as the otic epithelium (29).

Numerous genetic analyses of DF3R3 families have identified mutations in the POU3F4 gene. These include intragenic mutations, partial or complete deletions of the gene, as well as deletions, inversions, and duplications of the POU3F4 genomic region not encompassing the POU3F4 coding sequence (8). Clinical characterizations of affected individuals and their specific mutations in POU3F4 have also been described (8). Nevertheless, little is known about how such mutations affect the normal function of the POU3F4 protein, which leads to the characteristic inner ear defects and deafness. Nor is it known how POU3F4 contributes to the normal development of the inner ear.

Here we report three novel mutations in the POU3F4 gene identified in three Korean families carrying X-linked hereditary hearing loss and the clinical characterization of affected family members. In addition, we performed molecular modeling and various in vitro assays to understand the molecular basis of the inner ear defects caused by these mutations.

MATERIALS AND METHODS

Subjects and clinical evaluations. Two Korean families exhibiting an X-linked inheritance pattern and one Korean family in which X-linked inheritance was plausible were ascertained at the Department of Otology-Neurology, Yonsei University College of Medicine, Seoul, South Korea. The proband of each family was subjected to detailed clinical evaluations including medical history, otopneurologic examinations, audiologic testing, and CT of the temporal bone. The clinical evaluations were also performed on other members of the families, including affected males and the female carriers. For audiologic testing, either brainstem-evoked response audiometry (BERA) or pure tone audiometry (PTA) was performed in line with the age of the patient, and the pure tone average was calculated with thresholds at 0.5, 1, 2, and 4 kHz. High-resolution temporal bone CT was performed with a 16 row multi-detector CT scanner (SOMATOM Sensation 16; Siemens, Erlangen, Germany) by using a standard temporal bone protocol (18). Contiguous 0.7-mm scans of the temporal bone were acquired in the axial plane and reformatted coronally with 1.0-mm increments. Written informed consent was obtained from participating individuals, and this study was approved by the Institutional Review Board of the Yonsei University College of Medicine.

Genetic analyses. For linkage analyses, genomic DNAs from the families were extracted from peripheral blood using the FlexiGene DNA extraction kit (Qiagen). They were genotyped with centromeric microsatellite marker DXS986 (57.36 cm from Marshfield Map) and telomeric marker DXS6803 (57.91 cm from Marshfield Map) flanking the DF3R3 locus (Xq21.1) using standard PCR conditions. The coding region of POU3F4 was amplified for direct sequencing using three sets of primers: 1) forward primer 5'-GTACCCCTGCTAGCTTTC-3' and reverse primer 5'-GGCGGATCATCTGGCAAT-3', 2) forward primer 5'-CCTACCCGACACTAACAAC-3' and reverse primer 5'-ACAGCAACCTTCTTCT-3', 3) forward primer 5'-CTCCATCGAAGGAGAATGTCG-3' and reverse primer 5'-GGACCCAGAATGATTGGATCC-3'. The amplified DNA fragments were sequenced with an ABI PRISM Big Dye Terminator Cycle Sequencing Kit (V3.1) and an ABI PRISM 310XL DNA analyzer (Applied Biosystems). Data were analyzed by using ABI Sequencing Analysis (v.5.0) and Lasergene-SeqMan software. The resulting sequences were compared with the POU3F4 sequence from GenBank (accession no. NM_000307). We also sequenced 70 Koreans with normal hearing to determine whether the mutations were present in the unaffected Korean population.

Molecular modeling. The crystal structure of POU2F1/Oct-1 was used as a template to build a model of wild-type and mutant POU3F4 proteins. Modeling was performed with the WHAT IF software (34) with standard parameter settings and protocols as described previously (4, 9). The details of the modeling protocol, including files used, sequence alignment, parameter choices, etc., are available from http://www.cmbi.ru.nl/~hvensenl/POU3F4/.

Plasmid construction. To construct expression vectors for wild-type and mutant POU3F4 proteins, the full-length open reading frame (ORF) of the single-exon POU3F4 gene was amplified by PCR from the genomic DNA of normal or affected males and sub-cloned into the pcDNA3 expression vector. The primer pairs used were 5'-atgaattcat-gegaccagctcgtc-3' and 5'-atgaegegctctagatcagaaacg-3'. Oligonucleotides encoding the hemagglutinin (HA) epitope were also inserted at the 5' of the POU3F4 ORF.

Expression and purification of recombinant POU3F4 protein. A glutathione S-transferase (GST) recombinant POU3F4 plasmid was constructed by subcloning the digested fragment containing whole POU3F4 sequences into pGEX-4T-1 Kpl/RecO RI site. GST fusion proteins were purified from the respective Escherichia coli BL21 extracts with glutathione-Sepharose (Pharmacia, Piscataway, NJ) according to standard procedures (14).

Electrophoretic mobility shift assay. The sequences of the double-stranded oligonucleotides used to detect the DNA-binding activities of POU3F4 were as follows: 5'-CAATATGCTAATCAATATATGCTAAT-3'. The reaction mixture for electrophoretic mobility shift assay (EMSA) contained 20 mM Tris·HCl, pH 7.6, 1 mM diithiothreitol, 2 mM MgCl2, 1 mM EDTA, 10% glycerol, 1% NP-40, 1 μg poly(dI-dC), and 2 μg purified recombinant GST-POU3F4 fusion proteins. Unlabeled oligonucleotides were added into the reaction mixture and incubated for 10 min at room temperature. [32P]-labeled probe DNA (300,000 cpm) was added, and the binding reaction was allowed to proceed for another 20 min. Mixtures were resolved on 8% polyacrylamide gels at 150 V for 4 h. Gels were dried and subjected to autoradiography.

Transcription reporter assays. The luciferase reporter plasmids were constructed by inserting either the upstream promoter region of human POU3F4 gene (~482 to +25), or two or three copies of the POU3F4 binding element (CAATATGCTAAT) into the pGL2 basic vector (21). C3H10T1/2 cells plated in 24-well plates were cotransfected with 300 ng of either wild-type or mutant POU3F4 expression plasmid, or both plasmids together, 150 ng of the luciferase reporter plasmid, and 20 ng of SV40-a-A myla plasmid for the transfection efficiency control. The transfected cells were incubated for 24 h and subjected to the luciferase assay according to the manufacturer’s protocol (Promega). Transfection efficiencies in each condition were normalized with renilla luciferase activity, which was under the control of a SV-40 promoter. Results were plotted based on at least three independent experiments.

RESULTS

Clinical characterizations of families carrying X-linked deafness. The pedigree of family SV08-18 showed a typical X-linked recessive inheritance pattern of hearing loss (Fig. 1A).
PTA measurements indicated that the proband of this family (IV-2, 6 yr) had a severe mixed type of hearing loss (Fig. 1B). Three other affected males (III-3, 36 yr; III-6, 29 yr; III-7, 16 yr) also showed similar patterns of hearing loss, but the thresholds were higher than that of the proband (Fig. 1B). Although longitudinal data on hearing loss were not available for these male family members, more severe hearing loss shown in older males especially in the sensorineural component suggested progressiveness of hearing impairment, as previously reported (8). Two female carriers in the family (III-2, III-4) had normal hearing (Fig. 1B).

The second family, SV08-17, also showed a typical X-linked recessive inheritance pattern of hearing loss: five males being affected in three generations (Suppl. Fig. S1). The proband was diagnosed with severe hearing loss by BERA [thresholds >60 dB nHL (decibel normal hearing level)] 1 mo after birth and is in the process of auditory rehabilitation with hearing aids. Another affected male in the family (II-4, 23 yr) was also diagnosed with hearing loss at the age of 6 yr and developed only limited verbal communication with hearing aids.

In the third family, SV08-21, the proband was diagnosed with severe hearing loss by BERA (75 and 90 dB nHL on the right and left side, respectively) at the age of 2 yr (Suppl. Fig. S1). Audiologic testing was not available for other members of the family, although the granduncle of the proband had suspected hearing loss. Since the proband and his mother carried the same mutation, the hearing loss appeared to be inherited in an X-linked recessive pattern in this family (Fig. 2; data not shown).

Further CT scans performed on six patients from all three families revealed that the defects of the temporal bones were comparable for all the patients examined and were characteristic of DFN3 (8, 27), including a wide fistulous connection between the basal turn of the cochlea and the IAC, and defects in the cochlear modiolus (Fig. 1C; data not shown). No other medical or neurological deficits were identified in any of the affected family members.

**Linkage and mutation analyses.** Since the family histories and clinical evaluations of all three families were characteristic for DFN3, we performed linkage analyses using DXS986 and DXS6803 microsatellite markers. Deafness showed linkage to the DFN3 locus in these families (Suppl. Fig. S1), so we searched for mutations in the POU3F4 gene in the affected members of the families by directly sequencing the POU3F4 coding region. Sequence analyses in family SV08-18 revealed a point mutation at nucleotide 986, guanine to cytosine (c.986 G>C) (Fig. 2A). This nucleotide change converts an arginine to a proline at the amino acid position 329 (p.R329P), which is one of the most conserved residues in the POU homeodomain of the POU3F4 protein (Fig. 2E).

Sequence analyses of family SV08-17 identified a one-base pair (bp) deletion at nucleotide position 346 (c.346delG) (Fig. 2B). This mutation causes a frame shift that encodes 25 new amino acids followed by premature termination of the protein at amino acid position 141 (p.Ala116fs). This results in a truncated form of the POU3F4 protein lacking both DNA binding domains (Fig. 2D).

The affected members of family SV08-21 had an in-frame deletion of three nucleotides (c.927-929delCTC; Fig. 2C), resulting in a deletion of the amino acid serine (p.S310del) in the POU homeodomain (Fig. 2C).

**Structural analyses of the wild-type and mutant POU3F4 proteins.** The POU3F4 protein consists of an NH2-terminal domain important for transcriptional activity and two COOH-terminal DNA-binding domains. These DNA-binding domains consist of the POU-specific domain connected by a short linker region to the POU homeodomain (13, 20, 22) (Fig. 2D). All three mutations identified in this study were expected to affect DNA binding activity of the POU3F4 protein, because they affect one of these domains. To examine the effect of the mutations on...
The tertiary structure of the POU3F4 protein, molecular models of wild-type, p.R329P, and p.S310del POU3F4 proteins were built based on the known crystal structure of the POU2F1/Oct-1 protein (19).

The p.R329P mutation is located in the third α-helix of the POU homeodomain (Fig. 2E). This α-helix is not in direct contact with the DNA but is likely important for the overall structure of the POU homeodomain. The homology model suggests that α-helical structure will remain after deletion of the serine residue (p.S310del) (Fig. 2H). However, since the absence of one residue will cause a shift of one position for all subsequent residues, disrupting normal interactions. The details of the modeling are also available from http://www.cmbi.ru.nl/hvensela/pou3f4/.

The serine residue at position 310 is located in the middle of the second α-helix of the POU homeodomain (Fig. 2E). This helix is not in direct contact with the DNA but is likely important for the overall structure of the POU homeodomain. The homology model suggests that α-helical structure will remain after deletion of the serine residue (p.S310del) (Fig. 2H). However, since the absence of one residue will cause a shift of one position for the subsequent residues in this helix, this will have dramatic effects on the stability of this helix because several hydrophobic interactions will get lost and a polar residue will become buried in the hydrophobic core of the protein. As a result, the interaction with the other helices is disturbed and the overall stability of the domain is decreased, which will severely reduce its DNA binding ability.
Effects of the POU3F4 mutations on DNA binding activity. Our modeling study suggested that all three mutations identified in DFN3 patients are likely affecting DNA binding ability by altering the tertiary structure of the DNA binding domains of the POU3F4 protein. To test this possibility, we conducted EMSA. Expression vectors encoding wild-type and mutant forms of POU3F4 protein were constructed, and the proteins were translated in vitro. The DNA-binding abilities of the in vitro translated and purified POU3F4 proteins were tested with the oligonucleotide probe (CAATATGCTAAT) that has been shown to specifically bind the murine Pou3f4 proteins (21). As shown in Fig. 3A, wild-type POU3F4 proteins bound strongly to the labeled oligonucleotides to form protein-DNA complexes (Fig. 3A, arrow). Specificity of the protein-DNA interaction was confirmed by competition experiments, in which addition of unlabeled oligonucleotide probes completely abolished the protein-DNA interactions. In contrast to the wild-type POU3F4, no detectable protein-DNA complexes were observed with any of the mutant forms of POU3F4. These results indicate that the mutations severely compromise the ability of the POU3F4 proteins to bind target DNA sequences.

Effects of the POU3F4 mutations on subcellular localization. The computer program “predictNLS” (5) predicts three putative nuclear localization signal (NLS) motifs in wild-type POU3F4. One of these is located in the POU-specific domain and the other two are in the POU homeodomain (Fig. 2D). The p.R329P mutation is located in one of the NLS motifs in the POU homeodomain, and the p.S310del mutation is located between the two NLSs in the POU homeodomain (Fig. 2D). The truncating mutation (p.Ala116fs) results in a protein that does not have any of the NLS motifs due to the lack of the DNA binding domains. To determine how these mutations affect nuclear localization of the POU3F4 proteins, expression vectors encoding wild-type or mutant POU3F4 proteins fused with the HA epitope were transiently expressed in the C3H10T1/2 cells (30). We chose this mouse mesenchymal cell line since Pou3f4 is mainly expressed in the mesenchyme surrounding the developing inner ear (28). Immunofluorescent analyses using anti-HA or anti-POU3F4 antibodies showed that wild-type POU3F4 proteins were localized exclusively in the nuclei of transfected cells (Fig. 3B; data not shown). In contrast, the majority of p.R329P or p.Ala116fs POU3F4 proteins, in which at least one NLS motif is disrupted, were found in both the cytoplasm and the nucleus (Fig. 3B). Although we expected normal nuclear localization for the p.S310del mutant, which preserved all three putative NLS motifs, POU3F4 proteins with this mutation also lost their normal subcellular localization and were found throughout the cells. This mislocalization could be due to the changes in the tertiary structure of the POU homeodomain where the NLS domains reside.

Effects of the POU3F4 mutations on transcriptional activities. The inability of the mutant POU3F4 proteins to bind to the target DNA sequence or to correctly localize in the nucleus strongly suggested that the transcriptional activity of the mutant POU3F4 proteins would also be severely compromised. To test this, we constructed a reporter plasmid, in which expression of the firefly luciferase gene is regulated by the promoter region (from −472 to +25 bp) of the human POU3F4 gene, which has been shown to be directly regulated by the POU3F4 protein itself (21). The reporter plasmid was cotransfected with the plasmid encoding either wild-type or mutant POU3F4 into C3H10T1/2 cells, and the ability of each POU3F4 protein to transactivate the reporter gene was assessed.
by measuring the luciferase activity in the transfected cells. In this system, wild-type POU3F4 protein activated the reporter gene expression almost threefold, but all three mutant POU3F4 proteins failed to activate the gene expression (Fig. 4B), indicating that the POU3F4 mutations completely abolish the transcriptional activity of POU3F4 proteins. Similar effects were observed with another reporter construct whose luciferase expression is under the control of two or three copies of the POU3F4 recognition element (CAATATGCTAAT) (21) (data not shown). Next, we tested to see if the mutant POU3F4 proteins could act as dominant-interfering variants. When both wild-type and any of the mutant POU3F4 proteins were coexpressed, the reporter expression activated by wild-type POU3F4 protein was not affected, indicating that the mutant POU3F4 proteins did not inhibit normal transcriptional activity of wild-type proteins (Fig. 4B). These results demonstrate that the three mutations identified in the DFN3 patients cause functional nulls of the POU3F4 protein.

**DISCUSSION**

We identified three novel mutations in the POU3F4 gene in three Korean families displaying X-linked inheritance of hearing loss. Two of the mutations (p.R329P and p.S310del) occur in the POU homeodomain, and the third mutation (p.Ala116fs) causes a premature termination, resulting in a protein lacking the entire DNA-binding domains (Fig. 2). Like the three mutations we have studied here, most of the POU3F4 mutations identified in DFN3 patients specify amino acid changes in regions that encode the DNA-binding domains, the majority being in the POU homeodomain (8), suggesting that loss of DNA binding ability may be a common pathological mechanism at the molecular level. Indeed, protein modeling and several molecular analyses demonstrate that the POU3F4 mutations severely disrupt the DNA-binding ability of POU3F4, thereby completely abolishing the transcriptional activity of the protein (Figs. 3 and 4). The mutant POU3F4 proteins failed to inhibit normal transcriptional activity of wild-type POU3F4, excluding the possibility that the mutant proteins act as dominant-interfering variants. Overexpression of the mutant POU3F4 proteins in C3H10T1/2 cells did not seem to have any obvious deleterious effects on normal cell behaviors such as cell proliferation or cell death (data not shown). Together, these observations strongly suggest that the hearing loss in DFN3 is caused by the loss of function of POU3F4 protein, rather than by gain of ectopic functions of mutant proteins. Clinical evaluations of DFN3 patients in this study are consistent with previously published reports that demonstrated no clear genotype-phenotype correlation between the different types of the POU3F4 mutations and the inner ear (20).

Mutations in POU4F3, another POU domain transcription factor, have been implicated in autosomal dominant hearing loss DFNA15 (32). Similar to our POU3F4 results, molecular analyses of POU4F3 mutations identified in DFNA15 patients showed that the mutant POU4F3 proteins lack transcriptional activity due to the loss of nuclear localization and DNA-binding activity (6, 35). Thus, the two POU family transcription factors share a common molecular pathological mechanism, whereby transcription of target genes essential for inner ear development is affected. Consistent with its expression in the hair cells, POU4F3 has been shown to regulate genes important for hair cell differentiation such as Gfi1 and Lhx3 (15, 16). Similarly, the hearing loss in DFN3 by POU3F4 mutations is most likely associated with lack of expression of downstream target gene(s) that plays critical roles in inner ear development, especially in the mesenchymal remodeling and otic epithelial-mesenchymal interactions. Only a few target genes of POU3F4 have been identified to date in other tissues: proglucagon gene in the α-cells of the pancreas (17), D1A dopamine receptor gene in the striatum (25), and human involucrin gene in the epidermis (36). However, little is known about downstream targets of POU3F4 in the peri-otic mesenchyme where POU3f4 is actively expressed (28). The temporal bone CT scans of DFN3 patients as well as the POU3f4 knockout inner ear phenotypes suggest that most of the inner ear malformations were found in the structures derived from the mesenchyme (23, 28). Therefore, elucidating the downstream targets of POU3F4 in the peri-otic mesenchyme will be crucial to understand how POU3F4 normally contributes to the mesenchymal patterning in inner ear development.

While the genes regulated by POU3F4 are unclear, previous studies provided hints as to how the POU3F4 gene is regulated in the peri-otic mesenchyme during inner ear development. Tbx1, a member of the T-box gene family of transcription factors and known causative gene for DiGeorge syndrome, is expressed in both the otic epithelium and peri-otic mesenchyme (1). Studies using tissue-specific knockout mice suggest that Tbx1 expressed in the mesenchyme is required for the mesenchymal expression of Pou3f4 (1), although it is not clear if Tbx1 directly regulates the mesenchymal Pou3f4 expression. Consistent with this, a genetic interaction between Tbx1 and Pou3f4 has been demonstrated to be necessary for normal cochlear formation (3). Interestingly, expressions of both Tbx1 and Pou3f4 in the mesenchyme are dependent on Sonic hedgehog (31). Thus, a molecular pathway of Shh-Tbx1-Pou3f4 in
the peri-otic mesenchyme has been proposed to be involved in the normal cochlear patterning (2). Further analyses of the molecular networks regulating POUSF4 as well as downstream genes regulated by POUSF4 are warranted to produce a better understanding of the roles of POUSF4 in normal inner ear patterning, as well as the causative mechanism of DFN3.

ACKNOWLEDGMENTS

We thank Drs. Dennis T. Drayna and Doris K. Wu for critical reading of the manuscript. We also thank Jin Ahn for technical assistance.

GRANTS

This work is supported by Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea, Grant A080588 (J. Bok, U.-K. Kim), by a research grant of the Life Insurance Philanthropy Foundation, by the Korean Ministry of Education through the Brain Korea 21 project (H. K. Lee, S.-J. Choi), and by The Netherlands Bioinformatics Centre (H. Venselaar).

REFERENCES


